Screener
Celldex Therapeutics CLDX Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Celldex Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: Celldex Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091984
| Line item | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|
| Net proceeds from stock issuances | 323,832 | — |
| Proceeds from issuance of stock from employee benefit plans | 1,152 | 265 |
| Net cash provided by financing activities | 324,984 | 265 |
| Net increase (decrease) in cash and cash equivalents | 18,583 | (5,312) |
| Cash and cash equivalents at beginning of period | 28,871 | 28,356 |
| Cash and cash equivalents at end of period | $47,454 | $23,044 |
| Non-cash investing activities | ||
| Accrued construction in progress | $577 | $49 |
Item 1. Unaudited Financial Statements
FAQ
- What is Celldex Therapeutics's net change in cash?
- Celldex Therapeutics (CLDX) reported net change in cash of $11.73M in Q2 2026.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about Celldex Therapeutics's net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude